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Objective. To assess the therapeutic efficacy of local injections of botulinum toxin type A (Btx-A) in improving blood flow to the hands of patients with Raynaud's phenomenon (RP) secondary to scleroderma.
Methods. In this randomized, double-blind, placebocontrolled clinical trial, patients with sclerodermaassociated RP received Btx-A (50 units in 2.5 ml sterile saline) in one randomly selected hand and sterile saline (2.5 ml) in the opposite hand. Follow-up at 1 and 4 months postinjection included laser Doppler imaging of hands, patient-reported outcomes, and physical examination. We compared outcomes using paired t-tests and population-average generalized models with generalized estimating equations.
Results. Of 40 patients enrolled, 25 had limited scleroderma and 15 had diffuse scleroderma. From baseline to 1-month follow-up, there was a greater reduction in average blood flow in Btx-A-treated hands compared to placebo-treated hands. The model estimated that this difference was statistically significant (average difference 230.08 flux units [95% confidence interval 256. 19, 23 .98], P for interaction 5 0.024). This difference was mainly influenced by patients with longstanding RP and diffuse scleroderma. Change in blood flow at 4-month follow-up was not significantly different between groups. Clinical measures (QuickDASH, McCabe Cold Sensitivity Score, pain on a visual analog scale, and Raynaud's Condition Score) improved slightly for Btx-A-treated hands.
Conclusion. Our laboratory-based laser Doppler imaging flow data do not support using Btx-A to treat RP in all scleroderma patients. The secondary clinical outcomes suggest some positive effect, but its clinical meaningfulness is questionable. The role of Btx-A in treating RP should be further studied with more homogeneous patient populations and in unique clinical situations such as acute digital ischemia.
Raynaud's phenomenon (RP) is present in most patients with scleroderma and is often the presenting symptom of the disease process (1) . This painful and debilitating condition results from increased vascular reactivity combined with structural vascular disease in the cutaneous arterial supply to the digits (1) (2) (3) . RP strongly impacts patient quality of life (4) and can result in recurrent digital ulcers and critical ischemic events in scleroderma (5) , which may require partial amputations of the affected digits.
Despite the heavy burden of RP on patients with scleroderma, treatment options are not ideal. Symptom control and prevention of disease progression rely on nondrug measures coupled with pharmacologic treatment with vasodilators such as calcium-channel blockers, phosphodiesterase 5 inhibitors, endothelin receptor antagonists, and prostacyclins (1) . If this treatment fails or the patient cannot tolerate its side effects, patients are left with few options. Surgical treatment, requiring time-and skillintensive microsurgery, consists of periarterial sympathectomy and is generally limited to patients with RP refractory to medical therapy (6) . Repair of larger vessel occlusive disease is a very uncommon surgical option.
Botulinum toxin type A (Btx-A) injected locally into the hand is considered a possible alternative therapy for RP. Several mechanisms are proposed for the potential effect of Btx-A on RP, involving the inhibition of sympathetic adrenergic or cholinergic vasoconstriction, inhibition of sensory nerves, and/or endothelial exocytosis of endothelin 1 (3, 7) . Studies in animal models show a positive effect of Btx-A increasing vascular blood flow by inhibiting sympathetic vasoconstriction (8) . Observational studies involving patients with RP show that Btx-A injected into the perivascular space of the affected digits provides significant symptomatic relief (9) (10) (11) (12) (13) (14) (15) . Most of these studies are retrospective case series (10, 11, 13, 15) ; the 2 prospective cohort studies reported have low internal validity due to lack of randomization, placebo controls, and/or blinding (12, 14) . Most studies have had heterogeneous patient populations, including patients with primary RP, secondary RP associated with other connective tissue disorders, and/ or acute digital ischemia (10, 11, 13, 15) . Only 2 studies have focused specifically on RP secondary to scleroderma (12, 14) , limiting interpretation of the evidence for this patient population. Anecdotal evidence from 1 case series suggests that patients with scleroderma may be less responsive to Btx-A injections compared to other patients with RP (11). We conducted a randomized, double-blind, placebo-controlled clinical trial to determine if local injections of Btx-A would be an efficacious intervention to control RP by improving blood flow and symptoms in patients with RP secondary to scleroderma.
PATIENTS AND METHODS
Study design and setting. This was a randomized, double-blind, parallel-group, placebo-controlled clinical trial conducted at the Johns Hopkins Scleroderma Center in Baltimore, MD. Participants were enrolled between January and May 2015; follow-up was completed by September 2015.
Participants. Eligible participants included adults age $18 years with bilateral RP (16) and scleroderma. Patients enrolled had a diagnosis of scleroderma according to the American College of Rheumatology (ACR) preliminary classification criteria (17) and the ACR/European League Against Rheumatism 2013 classification criteria (18) , had at least 3 of 5 features of CREST syndrome (calcinosis, RP, esophageal dysmotility, sclerodactyly, telangiectasias), or had definite RP, abnormal nailfold capillaries, and a scleroderma-specific autoantibody. Patients were excluded if they had active infection in either hand, acute digital ischemia, a history of myasthenia gravis, any known allergies or hypersensitivity to botulinum toxin preparations, had previously received botulinum toxin vaccine, had previously undergone upper extremity vascular surgery (including surgical sympathectomy), were currently receiving aminoglycoside antibiotics, or were pregnant or lactating.
Interventions. Participants received Btx-A (onabotulinumtoxinA; Allergan) in one randomly selected hand and sterile saline in the opposite hand. Injections were performed by 2 hand surgeons (EM and SDL) using a 3-ml syringe and a 30-gauge needle through the dorsal surface in 7 locations per hand: adjacent to the second, third, and fourth common digital arteries through the web spaces (10 units each 5 30 units or 1.5 ml) and the radial side of the index finger proximal phalanx base, the ulnar side of the small finger proximal phalanx base, and each side of the thumb proximal phalanx base (5 units each 5 20 units or 1 ml). Figure 1 illustrates the injection protocol. Hands in the experimental group received a total of 50 units of Btx-A, reconstituted in 2.5 ml of sterile saline. Hands in the control group received a total of 2.5 ml of sterile saline as placebo.
Randomization, blinding, and allocation concealment. The study pharmacists generated a random sequence with blocks of 4 patients for treatment group allocation in a 1:1 ratio using Microsoft Excel 2007. Study participants and all study team members (including hand surgeons and the study statistician), except for the study pharmacists, were blinded with regard to treatment allocation and the size of randomization blocks. Both injections were clear and visually not distinguishable. The study coordinator enrolled all study participants. The study pharmacists assigned treatment allocation and maintained allocation concealment throughout the study period.
Data collection and outcome measures. Follow-up consisted of a safety phone call (or optional in-person study visit) at 7 days (63 days) postinjection and in-person study visits at 1 month (68 days) and 4 months (615 days) postinjection. In-person visits included noninvasive laser Doppler imaging of hands, pulse oximetry, and physical examination for digital ulceration. Patient-reported outcomes were collected specifically for each hand, using instruments that have been validated in other upper extremity and hand conditions (QuickDASH [19] , McCabe Cold Sensitivity Score [20] , and pain on a visual analog scale [VAS] [21] ) and specifically for RP (Raynaud's Condition Score [RCS] [22] ). Patients were asked at each visit their opinion on which hand they thought had been treated with Btx-A; this helped in assessment of the success of blinding (23) .
The primary outcome measure was the change in blood flow from baseline to 1-month follow-up, measured using an LDI2-IR scanner (Moor Instruments). By scanning tissues with a low-energy laser beam, laser Doppler imaging quantifies the Doppler effect between red blood cells and the scanner to determine blood flow speed, allowing noninvasive, objective measurement of superficial cutaneous blood flow (24) . Laser Doppler imaging has been proposed as an outcome measure for microvascular research (25) and has been used extensively for scleroderma-associated secondary RP (24, (26) (27) (28) (29) . The study room temperature was maintained at 778F (258C), and the study staff waited 30 minutes after the patient arrived in the room to allow temperature equilibration before performing scans. Laser Doppler imaging readings were analyzed using LDI Review version 6.0 software (Moor Instruments), plotting regions of interest including the second, third, and fourth digits, limited by a line from the fourth web space to the lateral aspect of the second digit over the flare of the metacarpophalangeal joint. Mean flux units within this region were calculated, and the results of 3 consecutive scans were averaged for each visit. Within-patient intraclass correlation of consecutive scans of each hand was 95.6%, calculated using a 3-level linear mixed-effect model with participant and treatment as random intercepts.
Secondary outcome measures were the change in blood flow to 4 months postinjection, patient-reported outcomes (QuickDASH, McCabe Cold Sensitivity Score, and pain on a VAS) at 1 month and 4 months postinjection, and weekly RCS completed until 17 weeks postinjection. Tertiary outcome measures were the number of active digital ulcers per physical examination (defined clinically by the investigators) and findings on standardized photography of the digits.
Data on weekly ambient temperature at study participants' zip codes were collected from a publicly available web site (www.weather.com). Clinical characteristics relating to disease severity were tabulated from a prospective database maintained at the Johns Hopkins Scleroderma Center, including history of renal crisis or pulmonary hypertension, scleroderma subtype, diagnosis year, RP onset year, and Medsger RP severity score. The Medsger severity scale is a set of validated severity grading scales for each organ system involved in scleroderma. The scale for peripheral vascular involvement classifies patients as follows: grade 0 5 no RP, grade 1 5 RP, grade 2 5 digital pitting scars, grade 3 5 digital tip ulcerations, grade 4 5 digital gangrene (30) .
Sample size. Using data from the literature (31), a sample of 40 study participants (or 80 paired blood flow measurements) was estimated to provide at least 80% power to detect a paired difference of 1.3 kHz, equivalent to 87% difference from baseline in blood flow measurements, with a Type I error of 5% and conservatively assuming a within-person correlation of blood flow measurements between 0.3 and 0.5 and standard deviation of ,2.9 kHz for the paired difference.
Statistical analysis. Continuous variables were summarized using means and SDs or medians and interquartile ranges (IQRs), as appropriate, and categorical variables were summarized using proportions. Using a paired t-test, an interim analysis was performed for the primary outcome measure once the first 20 patients had completed 1-month postinjection study visits. A stopping rule established that if either group was found to have significant improvement over the other, study enrollment and interventions would stop.
The final analysis assessed changes in blood flow and secondary outcome measures by fitting generalized linear population-average models with robust variance using generalized estimating equations and exchangeable working correlation structure. Models included treatment group (Btx-A versus placebo), time point (1 month versus baseline and 4 months versus baseline), and their interaction. Interaction terms tested whether blood flow (or secondary outcome) trajectories differed by treatment group. Unlike other secondary variables, RCS data included weekly measurements for the study duration (17 weeks). A separate model estimated changes in RCS over time, and, to adjust for ambient temperature, temperature data were included as a fixed effect in the model. Significance was set at an alpha level of #0.001 for the interim analysis, an alpha level of #0.049 for final analysis of the primary outcome measure (to account for the interim analysis) (32) , and an alpha level of #0.050 for all other analyses.
Before conducting data analysis or unblinding, 4 variables were defined for subgroup analysis: 1) cutaneous subtype (diffuse skin disease versus limited scleroderma), according to the classification system of LeRoy et al (33) ; 2) RP severity, quantified as the maximum peripheral vascular disease/RP score (from the Medsger severity scale) ever recorded from first scleroderma center visit to study enrollment; 3) years since RP onset; and 4) use of calcium-channel blockers at baseline. This analysis was intended for hypothesis generation rather than hypothesis testing, and to potentially guide future studies.
Ethical considerations. The study conformed to the Declaration of Helsinki ethical principles for medical research. Institutional Review Board (IRB) approval was obtained from the Johns Hopkins Medicine IRB (protocol no. NA_00087346). Three independent faculty members at our institution served as an Adverse Events Committee to monitor and oversee serious and/or unexpected adverse events. No major changes to the protocol were made during the study with regard to eligibility criteria, interventions, examinations, data collection, analytic methods, or outcome measures.
RESULTS
Patient characteristics. Forty patients were enrolled, all of whom completed 1-week postinjection phone calls and 1-and 4-month postinjection study followup visits. One patient chose the optional 1-week postinjection study visit; all others chose the safety phone call.
Of the study participants, 25 had limited scleroderma and 15 had diffuse scleroderma. Thirty-one patients (77.5%) were women and 9 (22.5%) were men. Their mean 6 SD age was 51.9 6 12.3 years (range 21-75), the median time since scleroderma diagnosis was 14 years (IQR 6-19.5), and the median time since RP onset was 15.6 years (IQR 10.7-23.2). The maximum Medsger score of severity of vascular disease ever recorded was 1 for 11 patients (28.21%), 2 for 15 patients (38.46%), and 3 for 13 patients (33.33%). One patient did not have the severity score recorded.
The most common comorbidities were hypertension (43%) and dyslipidemia (43%), followed by chronic obstructive pulmonary disease (15%), atrial fibrillation (10%), arthritis (8%), diabetes mellitus (3%), and coronary artery disease (3%). At baseline, 2 patients (5%) had a history of scleroderma renal crisis and 1 patient (3%) had pulmonary hypertension. Two patients (5%) were current smokers; 10 patients (25%) were former smokers. These 12 patients had a median of 20 pack-years (IQR 15.63-28.75).
At baseline, most participants (72.5%) were being treated with calcium-channel blockers for RP. Other drug therapy with vasoactive potential, not necessarily being used for the treatment of RP, included phosphodiesterase 5 inhibitors (17.5%), fluoxetine (12.5%), and losartan (12.5%). One patient was treated with oral bosentan for pulmonary hypertension throughout the study duration.
Outcome measure data at baseline. Baseline measurements of blood flow, QuickDASH score, McCabe Cold Sensitivity Score, VAS pain score, oxygen saturation, and number of active ulcers are shown in Table 1 . There were no significant differences between hands allocated to the Btx-A group and hands allocated to the placebo group.
Interim analysis. Our interim analysis comparing blood flow change from baseline to 1 month postinjection between groups did not show a significant difference (P 5 0.741). Therefore, study recruitment continued until the target sample size was achieved and follow-up was completed.
Laser Doppler imaging blood flow ( Table 1 ). The mean 6 SD baseline blood flow in hands allocated to the Btx-A group was 398.24 6 190.27 flux units, which was not significantly different from that in the placebo group Secondary outcome measures (Table 1) . Changes in QuickDASH scores were not significantly different between treatment groups at 1-month follow-up (P 5 0.504) or 4-month follow-up (P 5 0.388). Absolute scores were slightly lower in the Btx-A group than in the placebo group at baseline (3.42 points lower), 1-month follow-up (2.15 points lower), and 4-month follow-up (1.95 points lower); however, these between-arm differences were not statistically significant.
McCabe Cold Sensitivity Scores in the Btx-A group were slightly better than those in the placebo group (1.88 points lower at 1-month follow-up and 0.31 points lower at 4-month follow-up). However, these between-arm differences were not significant (P 5 0.834 and P 5 0.963, respectively). Rates of change from baseline in McCabe Cold Sensitivity Scores were not significant 1 month postinjection (P 5 0.938) or 4 months postinjection (P 5 0.906).
The change in VAS pain scores from baseline was not significantly different between study groups (P 5 0.683 at 1-month follow-up, P 5 0.327 at 4-month follow-up). VAS pain scores were slightly lower in the Btx-A group than in the placebo group at 1-month follow-up (0.37 cm lower) but not at 4-month follow-up (0.15 cm higher). These between-arm differences were not statistically significant (P 5 0.121 and P 5 0.585, respectively).
Oxygen saturation as measured by pulse oximetry was slightly higher in the placebo group than in the Btx-A group at 1-month follow-up (mean 95.21% versus 94.10%). However, the between-group difference was not statistically significant (P 5 0.318) and remained nonsignificant at 4-month follow-up (95.31% versus 92.49%; P 5 0.074).
Patient-reported RCS (scored 1-10, with 10 being severe) decreased by 0.18 points weekly in the Btx-A group (95% CI 0.13, 0.22) (P , 0.001) and by 0.14 points weekly in the placebo group (95% CI 0.11, 0.18) (P , 0.001). The interaction term comparing these slopes between groups showed weak evidence of statistical significance (P 5 0.063). After adjustment for weekly ambient temperature at the patient's zip code, there was evidence for a statistically significant difference between these 2 rates of decline (P 5 0.045), which suggested a faster decline in the Btx-A group (Figure 3) .
At baseline, 8 hands allocated to the Btx-A group (20%) and 10 hands allocated to the placebo group (25%) had active ulcers. The relative risk (RR) of developing new ulcers was 16.67% higher in hands allocated to placebo treatment than in hands allocated to Btx-A treatment at 1-month follow-up (RR 1.17 [95% CI 0.65, 2.10]) and 27% higher at 4-month follow-up (RR 1.27 [95% CI 0.68, 2.37]). These differences between groups were not significant (P 5 0.608 and P 5 0.447, respectively). Changes over time in the number of new ulcers were also not statistically significant at 1-month follow-up (P 5 0.697) or at 4-month follow-up (P 5 0.572). All patients were asked at each visit which hand they thought received Btx-A. At 1 week postinjection, 11 patients (27.5%) guessed correctly; 8 of these patients and 3 additional patients (27.5%) also guessed correctly at 1-month follow-up. At 4-month follow-up, 19 patients (47.5%) guessed correctly, of whom 11 had guessed correctly at previous visits. None of these correct guesses happened more often than would have been expected by chance (P . 0.999, P 5 0.706, and P 5 0.275, respectively).
Subgroup analysis. A subgroup analysis according to cutaneous subtype, RP disease duration, RP severity, and baseline treatment with calcium-channel blockers was performed for hypothesis generation and to potentially guide future research. This analysis showed that the negative trend observed in the full analysis was mainly driven by patients with longer time since RP onset (.15.56 years) and those with diffuse scleroderma ( Figure 2B ). Adverse reactions. Two participants (5%) experienced weakness of the intrinsic muscles of the hand after receiving study injections. Both cases appeared only in Btx-A-treated hands. The 2 patients reported weakness 7 days postinjection and fully recovered by 3 weeks in one case and 9 weeks in the other case. Both patients were able to guess correctly which hand had received Btx-A.
DISCUSSION
Btx-A, as administered in our study, did not significantly improve blood flow to the hands of patients with scleroderma-associated RP. In fact, the change in blood flow from baseline to 1-month follow-up declined more with Btx-A than with placebo (P for interaction 5 0.024). On average, blood perfusion decreased 30.08 flux units (7.7% from baseline) among hands allocated to the Btx-A group. Absolute blood flow at 1-month follow-up was also lower among hands allocated to the Btx-A group than among hands allocated to the placebo group (P 5 0.018).
Interestingly, patients reported slightly better outcomes for hand function (QuickDASH scores), cold sensitivity (McCabe Cold Sensitivity Scores), and pain (VAS pain scores) in the hands that were treated with Btx-A. However, these differences were not statistically significant. Patients also reported a greater reduction in RP severity as measured with the RCS (a validated patientreported scale of the impact of RP) in the hands that were treated with Btx-A. Although smaller than the reported minimum clinically important difference for changes in RCS (22) , this difference was statistically significant after adjustment for local ambient temperature (P 5 0.045).
We enrolled patients during winter and spring of a particularly cold year. This made interpreting our findings more complex, as most patients reported subjective relief in both hands over time. Fortunately, randomized withinpatient placebo controls allowed meaningful comparisons between Btx-A treatment and placebo.
Interestingly, a planned subgroup analysis showed that the overall negative results observed in the full analysis were mainly influenced by patients with longer time since RP onset (.15.56 years) and those with diffuse scleroderma. This suggests that differences in response to Btx-A may exist in subgroups of patients with scleroderma. We observed significantly worse blood flow among patients receiving calcium-channel blockers at baseline. However, this finding is likely not clinically important because our data also showed better McCabe Cold Sensitivity Scores (meaning less cold sensitivity) in patients receiving calciumchannel blockers (data not shown). Accounting for differences in responses in this subgroup may be important for future studies.
To our knowledge, this is the first randomized, placebo-controlled, double-blind clinical trial evaluating Btx-A injections in patients with RP secondary to scleroderma. In contrast to other studies, our study demonstrated a significant decrease in blood flow with Btx-A.
A first case series reported by Sycha et al in 2004 showed positive results with Btx-A in 2 patients, 1 with primary RP and 1 with RP secondary to mixed connective tissue disease (13) . Their promising results included subjective (VAS pain score) and objective (laser Doppler interferometry) RP outcomes. This was followed by a case series reported by Van Beek et al in 2007 (15) , in which 11 patients with RP associated with various connective tissue disorders received up to 100 units of Btx-A per treated hand. Almost all patients (82%), including those with limited or diffuse scleroderma, reported improvement in the severity and frequency of their vasospastic episodes. Unlike our study, Van Beek et al included patients with acute digital ischemia and did not objectively measure perfusion.
A larger, uncontrolled, retrospective case series showed similar results injecting 50-100 units of Btx-A into each hand, using laser Doppler imaging as an outcome measure (11) . A heterogeneous population of patients with primary and secondary RP was included, some of whom had critical ischemia. Blood flow increased by up to 425% in hands treated with Btx-A. Eighty-four percent of patients reported improvement in pain. Three patients with scleroderma participated in this study; 2 with diffuse disease had improved blood flow but no symptom relief, and 1 with limited disease had improved blood flow and 13 months of pain relief.
Observational studies reviewed by Iorio et al showed positive results (9) . Two additional prospective studies, which did not incorporate ideal controls, focused specifically on scleroderma patients and also showed benefits from Btx-A treatment (12, 14) . To our knowledge, robust studies using randomization, blinding, or placebo controls have not been reported.
It is important to recognize that the effect of an intervention measured in a controlled laboratory setting may have very different biologic implications compared to patient-reported clinical outcomes. Interestingly, our subjective, patient-reported measures suggested slight symptom relief in Btx-A-treated hands, as measured using patient-reported weekly RCS. Although the size of this effect was small, this finding may be important given that this subjective outcome was reported while patients were effectively blinded to treatment allocation. We also found small differences that favored Btx-A in other secondary outcomes (hand function, cold sensitivity, pain, and number of ulcers) but that were not statistically significant.
This apparent disconnect between patient-reported outcomes and objective vascular laboratory measures, such as laser Doppler imaging-determined blood flow, has been reported by others. Pauling et al did not find significant correlations between subjective results from an RCS diary and objective results from either laser speckle contrast imaging or infrared thermography (34). Neumeister et al found that scleroderma patients showed improvement in laser Doppler imaging blood flow despite not reporting subjective pain relief after Btx-A injections (11) .
Our study has several limitations. We chose instruments that were validated for hand and upper extremity conditions, but not specifically for scleroderma in the case of the McCabe and QuickDASH scales. We studied a heterogeneous group of scleroderma patients and showed that results were generally more favorable for patients with limited scleroderma and those with earlier RP, who may have more modifiable disease. Stratification into more homogeneous patient populations may benefit future studies. The role for Btx-A alone or in combination with another vasoactive drug was not studied. It also remains to be established whether Btx-A would be helpful in treating critical digital ischemia.
It is possible that the negative results are due in part to our screening methods. We may have included patients with larger vessel disease such as radial or ulnar artery occlusion, as we did not perform a prestudy Allen's test and did not perform digital arteriography or magnetic resonance arteriography before the study injections. This type of screening was implemented in some of the observational studies (9, 12, 15) . However, in the study by Uppal et al, screening of patients by arteriography was not reported, and positive results were nevertheless obtained (14) .
This study did not include an option for dose escalation in that we intended to evaluate a standardized injection protocol and dosing that would enhance patient safety and minimize risk of loss of hand function. We observed a lower incidence of intrinsic muscle weakness in our study (5%) compared to previous studies (9-27%) (9) . Previous studies used Btx-A doses from 10 to 100 units per treated hand. A dose as low as 10 units of Btx-A has been reported to show favorable results (9) . We used a more distal site of injection than reported in some studies (Figure 1) . We also did this to prevent hand weakness. The lower incidence of intrinsic muscle weakness observed in this study also limited unblinding from drug effects to a small proportion of our study population.
The study may have been underpowered to detect clinically meaningful changes in perfusion. Available data on perfusion from the literature are not reported in flux units, which meant that our power calculation was based on different units of perfusion (kHz) that are not convertible into flux units. We believe, however, that measurements in flux units capture more blood flow information than simple frequency.
Our study design was novel, and this was a major strength, as we had patients serve as their own controls. This provided methodologic advantages but also limited our ability to discern whether a high within-patient correlation might have biased our results toward the null, or to discern whether there could be any contralateral improvement after unilateral Btx-A treatment, which has been observed with digital sympathectomy (35) .
We considered multiple study designs, including using in-house cold challenge tests. We decided not to use a cold challenge test for several reasons. First, because the exact mechanism of Btx-A in the relief of vasospasm is not precisely understood and because prior studies have measured response of vasospasm to Btx-A primarily in a laboratory environment which may not correlate with response to treatment in the real world (9-15,36), we considered it important to measure longer-term changes in blood flow with patients otherwise going about their normal life in their normal environment. Second, cold challenges would have made our study logistics difficult due to patients serving as their own controls. Finally, the resulting measurements would have lacked comparability with previous Btx-A studies using laser Doppler imaging (10, 11, 13) .
Additionally, this study was conducted at a large tertiary center, which may have decreased the generalizability of our findings. Finally, we made our study follow-ups at 1 month and 4 months posttreatment. It is possible that benefit occurred earlier and then disappeared. However, previous reports suggested long-term benefit and we believed that prolonged benefit would be clinically important. It is possible that acute effects may help acute digital ischemia.
Findings for the primary outcome measure, change in blood flow from baseline to 1-month follow-up, do not support the use of Btx-A in the treatment of RP in all scleroderma patients without acute digital ischemia. However, secondary clinical outcomes suggested some benefit. Patient-reported severity of RP showed a small but statistically significant improvement in hands treated with Btx-A. Further research is needed to fully understand the role of Btx-A in the treatment of RP.
